对UPAR与针对癌症治疗而开发的抗体结合的结构基础. 对灵活性,连接体识别和分子成像的机械洞察力
Rex F Anane1, Anni Kumari2,3, Hari Venugopal4
1Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia.
Protein science : a publication of the Protein Society
|January 23, 2026
概括
一种新的抗uPAR抗体 (FL1) 重组了尿酶类型的血原激活体受体 (uPAR),增强了癌症治疗和PET成像. 这种结构洞察力改善了FL1-ADC的疗效和AE105成像用于癌症治疗监测.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 泌尿酸酶类型的等离子体激活受体 (uPAR) 是癌症治疗的关键标.
- uPAR向体AE105用于PET成像和光导向手术.
- 针对UPAR的抗体药物合物 (ADC) 在临床前癌症模型中显示出有前途.
研究的目的:
- 为了阐明抗UPAR抗体 (FL1) 与UPAR结合的结构基础.
- 了解FL1结合如何影响UPAR构成和连接体相互作用.
- 评估这些发现对Upar向癌症治疗和成像学的影响.
主要方法:
- 高分辨率冷电子显微镜 (cryo-EM) 用于确定FL1和UPAR的复杂结构.
- 表面等离子体共振 (SPR) 用于测量动力结合数据.
- 对UPAR形状变化和连接体结合亲缘关系的分析.
主要成果:
- 低温EM结构显示,FL1结合限制了UPAR域间灵活性,特别是N端LU域.
- 结合FL1会诱导一种开放的UPAR构造,使其天然配体的结合亲和力减少300倍.
- FL1结合使得对PET成像探头AE105的亲和力降低了25倍.
结论:
- 在UPAR中FL1结合诱导的形状变化对于其治疗和诊断应用至关重要.
- 这些发现支持FL1-ADCs用于向癌症治疗的使用.
- 降低的AE105结合亲和力使得使用PET成像对治疗疗效的纵向监测更容易.
更多相关视频
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
1.2K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.8K
相关概念视频
Ligand Binding and Linkage
5.5K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K
Ligand Binding and Linkage
4.0K
4.0K
Ligand Binding Sites
14.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K
Ligand Binding Sites
8.7K
8.7K
Targeted Cancer Therapies
8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.7K
Antibody Structure
65.4K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.4K
